In a development hailed as an “incredibly exciting” breakthrough, researchers have introduced a new predictive blood test capable of signaling the risk of breast cancer recurrence years before any tumors are detectable through traditional imaging. This advancement, often referred to as a “liquid biopsy,” offers a ray of hope, potentially revolutionizing how we monitor and treat breast cancer survivors. A …
